Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to ...

We recently compiled a list of the Top 12 Stocks to Buy According to Bourgeon Capital. In this article, we are going to take ...

a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the supplemental New Drug Application (sNDA) for UZEDY extended ...

Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

And good morning, good afternoon, and good evening. And thank you all for taking the time to talk about this important program for Teva, our Duvakitug program. If I can have the next slide.

Teva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Sanctuary Advisors LLC boosted its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 132.4% in the 4th quarter, Holdings Channel reports.The fund owned 81,643 ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...